文献速递造血干细胞移植与细胞治疗白血病

我们能否超越清髓性预处理(MAC)?在65岁以下接受异基因造血细胞移植、使用ATG-PTCy-CsA预防移植物抗宿主病的患者中比较MAC与减低强度预处理(RIC)

Can we move beyond myeloablative conditioning (MAC)? A comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxis.
PubMed 文献 · Br J Haematol · 2025-09-18

这项回顾性研究在65岁以下接受异基因造血细胞移植、统一采用抗胸腺细胞球蛋白(ATG)、移植后环磷酰胺(PTCy)和环孢素(CsA)预防移植物抗宿主病的患者中,经倾向性评分匹配比较清髓性预处理(MAC)与减低强度预处理(RIC)的结局。移植后2年总生存(MAC 68.6% vs RIC 65.9%,p=0.61)与非复发死亡(MAC 15.8% vs RIC 12.5%,p=0.26)均无统计学显著差异,但RIC组复发发生率显著高于MAC组(27.0% vs 16.1%,p=0.01)。

要点

  • 65岁以下患者移植后2年总生存MAC 68.6% vs RIC 65.9%,p=0.61,无统计学显著差异。
  • 2年非复发死亡MAC 15.8% vs RIC 12.5%,p=0.26,无统计学显著差异。
  • 复发发生率RIC 27.0% vs MAC 16.1%,p=0.01,RIC组显著更高。

核心结论

  • 在适合强化治疗的年轻患者中,MAC似乎提供更优的疾病控制且未伴随非复发死亡增加,支持MAC持续具有相关性。
  • 作者认为需要前瞻性研究进一步明确在现代移植物抗宿主病预防背景下预处理强度的作用。

研究设计与样本

  • 回顾性研究,比较65岁以下接受异基因造血细胞移植患者中MAC与RIC的结局。
  • 所有患者统一采用包含抗胸腺细胞球蛋白(ATG)、移植后环磷酰胺(PTCy)和环孢素(CsA)的移植物抗宿主病预防方案。
  • 应用倾向性评分匹配以减少混杂。

主要发现

  • 移植后2年总生存MAC 68.6% vs RIC 65.9%,p=0.61,无统计学显著差异。
  • 移植后2年非复发死亡MAC 15.8% vs RIC 12.5%,p=0.26,无统计学显著差异。
  • 复发发生率RIC 27.0% vs MAC 16.1%,p=0.01,RIC组显著更高。

局限性

  • 原文为回顾性研究。
  • 作者指出需要前瞻性研究进一步明确预处理强度的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic haematopoietic cell transplantation (HCT) offers a curative option for numerous haematological disorders; however, its myeloablative conditioning (MAC) regimens are associated with substantial toxicity. Reduced intensity conditioning (RIC) regimens were developed to mitigate transplant-related toxicity and broaden eligibility-particularly for older or medically unfit patients-though their use in younger, fit patients remains debated. In this retrospective study, we compared outcomes between MAC and RIC in patients aged younger than 65 years undergoing allogeneic HCT with a unified graft-versus-host disease (GVHD) prophylaxis regimen comprising anti-thymocyte globulin (ATG), post-transplant cyclophosphamide (PTCy) and ciclosporin (CsA). Propensity score matching was applied to reduce confounding. At 2 years post-transplant, there were no statistically significant differences in overall survival (OS) between the groups (MAC: 68.6% vs. RIC: 65.9%; p = 0.61) or in non-relapse mortality (NRM) (MAC: 15.8% vs. RIC: 12.5%; p = 0.26). However, relapse incidence was significantly higher in the RIC group (27.0%) than in the MAC group (16.1%; p = 0.01). These findings reinforce the continued relevance of MAC in younger patients who are candidates for intensive therapy, as it appears to offer superior disease control without a concomitant increase in NRM. Prospective studies are warranted to further delineate the role of conditioning intensity in the context of contemporary GVHD prophylaxis.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Alyamany R, Alnughmush A, Remberger M, et al. Can we move beyond myeloablative conditioning (MAC)? A comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxis. Br J Haematol. 2025. PMID: 40968076. doi:10.1111/bjh.70170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。